| Presentation Stage A | October 14(Wed.) 13:00-13:30 |
|---|
| Epsilon Molecular Engineering Inc. |
|
Naoto Nemoto CEO |
Introduction of our new drug modalities |
| Presentation Stage B | October 14(Wed.) 15:40-16:10 |
|---|
| Fujita Health University |
|
Takahashi Kazuo Department of Biomedical Molecular Sciences, Graduate School of Medicine |
Analytical platform for highly complex glycosylation of therapeutic or pathogenic proteinsProtein glycosylation influences characteristics such as folding, stability, protein interactions, and solubility. Therefore, glycan moieties of therapeutic proteins and proteins that are likely associated with ... |
| Presentation Stage C | October 14(Wed.) 11:00-11:30 |
|---|
| Systems Pharmacology Mie University Graduate School of Medicine |
|
Toshio Tanaka Professor |
Patient-Derived Xenograft Zebrafish Model(PDXZ) for Companion Diagnostics and Drug Discovery Screening |
| Presentation Stage C | October 14(Wed.) 13:00-13:15 |
|---|
| Showa University |
|
KIyoshi Yoshimura / Takuya Tsunoda Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics |
Invitation for joint clinical development with Showa University -Creating value by clinical data-The clinical data obtained from patient samples and patients themselves are very hurdles in facilities and organizations that have little contact with clinical sites, and ... |
| Presentation Stage C | October 14(Wed.) 13:15-13:30 |
|---|
| Showa University |
|
Wada Satoshi Department of Clinical Diagnostic Oncology,Clinical Research Institute for Clinical Pharmacology and Therapeutics,Showa University,Professor |
Development of new cancer treatments and search for biomarkersWe have explored target molecules for cancer therapy and have reported several novel molecules. We have also focused on post-translational modifications to enhance the cancer ... |
| Presentation Stage C | October 14(Wed.) 14:20-14:50 |
|---|
| Tokyo University of Pharmacy and Life Sciences The Center for Open Innovation |
|
Tomomi Furihata Professor |
Development of human conditionally immortalized cell-based blood-brain barrier models for central nervous system drug discoveryIn vitro blood-brain barrier (BBB) models are expected to be useful tools for central nervous system (CNS) drug development, and here we introduce new types ... |
| Presentation Stage C | October 14(Wed.) 15:00-15:30 |
|---|
| Tohoku University Graduate School of Pharmaceutical Sciences |
|
Kohji Fukunaga Department of Pharmacology |
Development of Diagnosis and Disease-Modifying Therapeutics for DementiaAlzheimer's disease (AD) is caused by neuroinflammation with amyloid beta accumulation in human brain. LBD including Parkinson's disease is caused by neurodegeneration by abnormal alpha-synuclein ... |
| Presentation Stage C | October 14(Wed.) 15:40-15:55 |
|---|
| MiRXES Japan K.K. (Presentation in English) |
|
Li-Foong Yoong Representative Director |
Tools and services for microRNA-based discovery, development, and diagnosis |
| Presentation Stage A | October 15(Thu.) 11:00-11:30 |
|---|
| Veneno Technologies Co. Ltd. |
|
Hikaru Taira Director |
Drug discovery targeting membrane proteins with high throughput screening technology for the next-generation drug modality, disulfide-rich peptidesWe are developing peptide drugs that target membrane proteins such as ion channels using disulfide-rich peptides (DRPs), a type of natural peptide that has a ... |
| Presentation Stage A | October 15(Thu.) 11:40-12:10 |
|---|
| Epsilon Molecular Engineering Inc. |
|
Hidenao Arai Manager of Business Development |
Introduction of our new drug modalities |
| Presentation Stage A | October 15(Thu.) 13:00-13:30 |
|---|
| SPERA PHARMA, Inc. |
|
Yamada Hideaki Principal Researcher |
Overview and trends of analytical methods required for development and quality control of antibody drugsMonoclonal antibody(mAb) drugs are valid therapeutics due to their high target specificity and have provided huge market value in recent years. mAb molecules are biologically ... |
| Presentation Stage A | October 15(Thu.) 14:30-14:40 |
|---|
|
BONAC CO,
Fukuoka Prefectural Bio Industry Center Promotion Conference |
|
Tomohiro Hamasaki |
Collaborative Research with Fukuoka Prefecture to Develop a Therapeutic Drug for COVID-19Novel coronavirus infections (COVID-19) are currently raging all over the world, and the development of a therapeutic agent for the disease is desired as soon ... |
| Presentation Stage A | October 15(Thu.) 14:40-14:50 |
|---|
|
KAICO.Co
Fukuoka Prefectural Bio Industry Center Promotion Conference |
|
MasahiroTaniguchi |
Development of new vaccines using silkworm systemKAICO Co., Ltd. is a startup company based on the silkworm technologies of the Faculty of Agriculture and the Faculty of Engineering of Kyushu University ... |
| Presentation Stage A | October 15(Thu.) 15:00-15:10 |
|---|
| Fukuoka Prefectural Bio Industry Center Promotion Conference |
|
Shigeki Sasaki |
Site- and base-selective RI-Labeling Method of Nucleic Acid Therapeutics for Biodistribution Study |
| Presentation Stage B | October 15(Thu.) 10:30-11:00 |
|---|
| Keio University Hospital |
|
Mitsuyo Ohmura Clinical and Translational Research Center, TR Div. |
| Presentation Stage B | October 15(Thu.) 13:10-13:40 |
|---|
| Nagasaki University |
|
Hitoshi Sasaki Professor and Director, Department of Hospital Pharmacy, Nagasaki University Hospital |
Novel drug delivery system nano-balls for cancer treatment.We have developed a novel drug delivery system nano-balls for cancer treatment. The nano-ball containing doxorubicin was effectively taken by cancer cells. After intraperitoneal administration ... |
| Presentation Stage B | October 15(Thu.) 15:00-15:30 |
|---|
| Doshisha University |
|
NISHIKAWA Kiyotaka Faculty of Life and Medical Sciences, Professor |
A new technology packaging two independent functions into one molecule: tissue/cell-specific targeting and regulation of the specific target.We will make a presentation about a new technology that enables to package two independent functions into one molecule: tissue/cell-specific targeting and regulation of the ... |
| Presentation Stage C | October 15(Thu.) 12:20-12:50 |
|---|
| Toyama Prefectural University |
|
Genji Iwasaki Vice director |
The research achievement of "Toyama Pharmaceutical Valley" Development Consortium in Toyama Prefectural University1. Nanoliposome eye drops to treat intractable eye diseases Eye drops are widely used for the anterior eye diseases, but there is no clinically effective formulation ... |
| Presentation Stage C | October 15(Thu.) 14:20-14:35 |
|---|
| Tokai National Higher Education and Research System Nagoya University |
|
Shunsuke Oishi Institute of Transformative Bio-Molecules (ITbM), Designated Assistant Professor |
Phenotype based peptide drug development - Cyclic peptide library for phenotype screeningPhenotypic screening with chemical library is a powerful tool to find novel bioactive compounds. Many small molecules have been discovered by this approach, some of ... |
| Presentation Stage C | October 15(Thu.) 15:05-15:20 |
|---|
| Tokai National Higher Education and Research System Nagoya University |
|
Kei Zaitsu In Vivo Real-time Omics Laboratory, Institute for Advanced Research, Nagoya University / Nagoya University Graduate School of Medicine Associate Professor |
PiTMaP: a new analytical platform for rapid metabolic profiling by combinational use of R-based data pipeline and a direct mass spectrometric technique without sample preparationProbe electrospray ionization tandem mass spectrometry, PESI/MS/MS, enables us to perform rapid and direct analysis of biogenic compounds in tissues without sample preparation (Zaitsu, Analytical ... |
| Presentation Stage A | October 16(Fri.) 11:00-11:30 |
|---|
| Hirosaki University |
|
Yoneyama Tohru Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine |
Tumor vasculature-targeted 10B delivery by a carbohydrate mimetic peptide boosts effects of boron neutron capture therapy10BPA is a powerful 10B drug used in current clinical trials of BNCT. For BNCT to be successful, a a high (500 mg/kg) dose of ... |
| Presentation Stage A | October 16(Fri.) 11:40-12:10 |
|---|
| KOBE GAKUIN UNIVERSITY |
|
Masaoki Takano Kobe Gakuin University Laboratory of Molecular Cell Biology School of Pharmaceutical Sciences |
Discovery of a novel factor X involved in male infertility |
| Presentation Stage A | October 16(Fri.) 13:00-13:30 |
|---|
| Hirosaki University |
|
Tanji Kunikazu Hirosaki University Graduate School of Medicine, Dept of Neuropathology, Associate Professor |
Dementia model mice suitable for treatment at early stageAnimal models of human diseases that recapitulate their clinical, biochemical and pathological features are indispensable for increasing our understanding of their underlying molecular mechanisms, which ... |
| Presentation Stage A | October 16(Fri.) 14:20-14:50 |
|---|
| Epsilon Molecular Engineering Inc. |
|
Masayuki Tsuchiya EVP, Drug discovery and Business development |
Introduction of our new drug modalities |
| Presentation Stage A | October 16(Fri.) 15:00-15:30 |
|---|
| Hirosaki University |
|
Kashiwakura Ikuo Hirosaki University Graduate School of Health Sciences, Project Professor |
Rapid and simple detection of radiation exposure dose using a small amount of biological sampleOxidative modification of serum albumin in diseases such as chronic renal failure, liver failure, primary hepatocellular carcinoma, and type 1 diabetes mellitus has recently been ... |
| Presentation Stage C | October 16(Fri.) 11:40-12:10 |
|---|
| Kagoshima University Graduate School of Medical and Dental Sciences |
|
Ken-ichiro Kosai Professor |
Next-Generation "Oncolytic Virus Immunotherapy"we developed a novel platform technology that enables efficient research on the next-generation OV (conditionally replicating adenovirus that can target cancers using multiple factors, m-CRA). |
| Presentation Stage C | October 16(Fri.) 14:20-14:50 |
|---|
| Waseda University |
|
Takeshi Maruyama Assistant Professor |
Epithelial cell-cell communication to facilitate the aberrant cell eliminationSo far, we have no effective strategies to defeat malignant cancers, and in many cases of pancreatic cancer, metastasis is found even in the early ... |
| Presentation Stage C | October 16(Fri.) 15:00-15:30 |
|---|
| Shiga University of Medical Science |
|
Nishi Eiichiro Department of Pharmacology, Professor |
Development of a novel anti-obesity therapy targeting a hepatic peptidaseThermogenesis is enhanced not only by cold exposure but also by feeding, which is considered as a partial defense mechanism against obesity. Although the molecular ... |
| Presentation Stage A | October 14(Wed.) 14:20-14:50 |
|---|
| Yamaguchi University |
|
UENO, Koji Research Associate |
Development of treatment for refractory cutaneous ulcers and prevention for postoperative complications with cell sheetsWe performed transplantation of bone marrow mononuclear cells (BMMNCs) for critical limb ischemia (CLI) patients in 1998 for the first time in the world. To ... |
| RM Stage | October 14(Wed.) 15:20-15:30 |
|---|
| Sysmex corporation |
|
Chikage Yamamoto Research & Industry Business Development Dev. |
| Presentation Stage C | October 15(Thu.) 11:00-11:30 |
|---|
| Medical electronics laboratory, Department of Science and Engineering, Tokyo Denki Univ. |
|
Yaguchi Toshiyuki Associate Professor |
| Presentation Stage C | October 15(Thu.) 14:35-14:50 |
|---|
| Tokai National Higher Education and Research System Nagoya University |
|
Ayae Sugawara-Narutaki Graduate School of Engineering Professor |
Synthetic elastin: A new material that reproduces the biological and mechanical properties of elastinWe have developed a recombinant protein (synthetic elastin) that can reproduce the biological and mechanical properties of elastin. Synthetic elastin dissolves in cold water and ... |
| Presentation Stage C | October 15(Thu.) 14:50-15:05 |
|---|
| Tokai National Higher Education and Research System Nagoya University |
|
Ryuji Kato Graduate School of Pharmaceutical Sciences Associate Professor |
Morphology-based Quality Prediction for Cell Quality ControlCellular products are not only functional as medicine/medical device in regenerative medicine, but also as animal-replacement cell models. More and more needs are increasing for ... |
| Presentation Stage C | October 15(Thu.) 15:30-16:00 |
|---|
| NIHON UNIVERSITY |
|
MATSUMOTO TARO Nihon University School of Medicine, Professor |
Low cost and minimally invasive cell-based therapy by use of dedifferentiated fat cellsDedifferentiated fat cells (DFATs) are multipotent mesenchymal stem cell (MSC)-like cells that are prepared from mature adipocytes by use of ceiling culture method. DFATs have ... |
| Presentation Stage C | October 15(Thu.) 16:00-16:30 |
|---|
| NIHON UNIVERSITY |
|
MIKI TOSHIO Nihon University School of Medicine, Professor |
Perspectives of Amnion-derived stem cellsRegenerative medicine and stem cell therapies hold the potential to alleviate the burden of many serious diseases, including a wide range of rare diseases. Among ... |
| RM Stage | October 15(Thu.) 11:30-11:40 |
|---|
| Nikon |
|
Atsushi Kitajima Healthcare Business Unit, Stem Cell Business Department, Business Planning Section |
| RM Stage | October 15(Thu.) 11:40-11:50 |
|---|
| Nikon CeLL innovation |
|
Toshiyuki Nakayama President |
CDMO Facility Introduction of Nikon CeLL innovation Co., Ltd.Nikon CeLL innovation Co. Ltd.(NCLi) announced an exclusive collaboration in 2015 with Lonza, a leader in pharmaceutical and biotech contract manufacturing, in order to establish ... |
| RM Stage | October 15(Thu.) 12:00-12:30 |
|---|
| Forum for Innovative Regenerative Medicine Standardization Committee (Fujifilm Corporation , Hitachi, Ltd., Astellas Pharma Inc) |
|
Ikuo Kawauchi*, Jun Otomo, Yutaka Yanagita |
Role of "standards" towards industrialization of regenerative medicineThe Forum for Innovative Regenerative Medicine (FIRM) states in FIRM VISION 2025 that "FIRM works to industrialize regenerative medicine and disseminate innovative treatments". While basic ... |
| RM Stage | October 15(Thu.) 15:00-15:30 |
|---|
| Sysmex corporation |
|
Toshio Katsuzawa Research & Industry Business Development Dev. |
Sysmex's new technology for regenerative medicineCounting of exosome, Cell culture analyzer, flow cytometry, etc. |
| Presentation Stage C | October 16(Fri.) 11:00-11:30 |
|---|
| The University of Electro-Communications / KUROGANE KASEI Co., Ltd. |
|
Shojiro A. Maki Graduate School of Informatics and Engineering Department of Engineering Science |
Innovation of NIR optical in vivo imaging technology.Our group innovates optical in vivo imaging probes. We have put on market "AkaLumine", "TokeOni", "SeMpai" having NIR emission activity (675 nm), already. NIR probes ... |
| Presentation Stage C | October 16(Fri.) 13:40-14:10 |
|---|
| Doshisha University |
|
MORITA Yusuke Faculty of Life and Medical Sciences, Professor |
Development of functional scaffold and tissue model with nano/micro-fiberIn order to promote tissue regeneration in regenerative medicine, we developed the functional scaffolds that enables to maintain cell activity for long period and construct ... |
| RM Stage | October 16(Fri.) 13:00-13:30 |
|---|
| Embody Science Corporation, Eurofins Analytical Science Laboratories Inc. |
|
Katsumi Katayama President, Technical Fellow |
Microbiological testing approach to regenerative medicine productsRaw materials derived from living human cells and the likes are often used in developing or manufacturing regenerative medicine products, and in the processing thereof, ... |
| RM Stage | October 16(Fri.) 13:40-14:10 |
|---|
| CellSeed Inc. |
|
Setsuko Hashimoto, Ph.D. Representative Board Director and President/CEO |
| Presentation Stage A | October 14(Wed.) 11:00-11:30 |
|---|
| Embassy of the Kingdom of the Netherlands (Presentation in English) |
|
Paul Zwetsloot Minister Counsellor, Economic Affairs |
The Netherlands technological frontrunner in LSH - Presentation by Dutch companies |
| Presentation Stage A | October 14(Wed.) 12:20-12:50 |
|---|
| Frost & Sullivan |
|
Ike Hiroshi Alliance-based Growth Strategy taken by Bio-industry Companies - Impact of COVID-19 |
Alliance-based Growth Strategy taken by Bio-industry Companies - Impact of COVID-19Frost & Sullivan offers a powerful experiential learning environment that integrates research and analysis, collaboration, and networking to help the CEO's growth teams identify opportunities ... |
| Presentation Stage C | October 14(Wed.) 13:40-14:10 |
|---|
| Waseda University |
|
Etsuro Ito Professor |
New antigen test for COVID-19: Ultrasensitive detection of S1 protein of SARS-CoV-2The COVID-19 pandemic has increased the demand for accurate, easy-to-use, rapid, and cost-effective antigen tests for clinical application. We propose a new antigen test for ... |
| healthTECH / ME-BYO Stage | October 14(Wed.) 14:10-14:20 |
|---|
| Novumcella Inc. |
|
Yasuyuki Kusuhara CEO |
Health management with enjoying your favorite music by high performance earphoneNovumcella Inc. is developing a earphone IT system by using Personal Life Repository which is licensed. The high performance earphones can collect pulse wave, oxygen ... |
| healthTECH / ME-BYO Stage | October 14(Wed.) 14:20-14:30 |
|---|
| Mediaid Corporation |
|
Hiroshi Yajima CEO |
Introducing "LifePalette", a communication platform based on PHR |
| healthTECH / ME-BYO Stage | October 14(Wed.) 14:30-14:40 |
|---|
| Arteryex. inc. |
|
Dongying Li CEO |
health info platform |
| healthTECH / ME-BYO Stage | October 14(Wed.) 15:05-15:15 |
|---|
| CAC Corporation |
|
Yutaka Matsumoto Healthcare IT Group Solution Manager |
| Presentation Stage C | October 15(Thu.) 13:00-13:30 |
|---|
| Research Center for Smart Biosensing, Hiroshima University |
| healthTECH / ME-BYO Stage | October 15(Thu.) 11:10-11:20 |
|---|
| Mediaid Corporation |
|
Hiroshi Yajima CEO |
Introducing "LifePalette", a communication platform based on PHR |
| healthTECH / ME-BYO Stage | October 15(Thu.) 11:20-11:30 |
|---|
| Novumcella Inc. |
|
Yasuyuki Kusuhara CEO |
Health management with enjoying your favorite music by high performance earphoneNovumcella Inc. is developing a earphone IT system by using Personal Life Repository which is licensed. The high performance earphones can collect pulse wave, oxygen ... |
| healthTECH / ME-BYO Stage | October 15(Thu.) 12:30-13:50 |
|---|
| Association for ME-BYO Industry Creation |
|
Association for ME-BYO Industry Creation |
| healthTECH / ME-BYO Stage | October 15(Thu.) 14:00-15:10 |
|---|
| Office for Strategic Policy and ICT Promotion, TOKYO METROPOLITAN GOVERNMENT |
| healthTECH / ME-BYO Stage | October 15(Thu.) 15:20-15:30 |
|---|
| Arteryex. inc. |
|
Yu Onozawa CHO |
health info platform |
| healthTECH / ME-BYO Stage | October 16(Fri.) 11:20-11:30 |
|---|
| Novumcella Inc. |
|
Yasuyuki Kusuhara CEO |
Health management with enjoying your favorite music by high performance earphoneNovumcella Inc. is developing a earphone IT system by using Personal Life Repository which is licensed. The high performance earphones can collect pulse wave, oxygen ... |
| healthTECH / ME-BYO Stage | October 16(Fri.) 11:30-11:40 |
|---|
| Mediaid Corporation |
|
Hiroshi Yajima CEO |
Introducing "LifePalette", a communication platform based on PHR |
| healthTECH / ME-BYO Stage | October 16(Fri.) 13:40-14:40 |
|---|
| Association for ME-BYO Industry Creation |
|
Isa Okajima |
| healthTECH / ME-BYO Stage | October 16(Fri.) 15:40-15:50 |
|---|
| CAC Corporation |
|
Yutaka Matsumoto Healthcare IT Group Solution Manager |
| Presentation Stage A | October 14(Wed.) 11:40-12:10 |
|---|
| National Institute of Genetics |
|
Shinya Miyagishima Professor |
| Presentation Stage A | October 14(Wed.) 15:00-15:05 |
|---|
| The University of Tokyo |
|
Masaharu ISHII Professor |
Strategy for Bioeconomy-based Society -Technology Development and Industrialization |
| Presentation Stage A | October 14(Wed.) 15:05-15:20 |
|---|
| Japan Association Of Bioindustries Executives (JABEX) |
|
Yuji SAKAMOTO Deputy General Of Secretary |
| Presentation Stage A | October 14(Wed.) 15:20-15:35 |
|---|
| Ministry of the Environment, Japan |
|
Tomoyuki IZUMI Deputy Director, Recycling Promotion Office, Environmental Regeneration & Material-Cycle Department |
Toward technology development and expanding use of bioplastics supporting carbon-neutral society |
| Presentation Stage A | October 14(Wed.) 15:35-15:50 |
|---|
| New Energy and Industrial Technology Development Organization (NEDO) |
|
Chikako HAYASHI Project Manager, Bioeconomy Promotion Division, Materials Technology and Nanotechnology Department |
Smart cell creation technologies for the production of useful substances by plants and microorganisms |
| Presentation Stage A | October 14(Wed.) 15:50-16:05 |
|---|
| Sustainable Management Promotion Organization (SuMPO) |
|
Masayuki KANZAKI Director, LCA Department |
CO2 reduction potential based on CNF technology toward Decarbonized society |
| Presentation Stage A | October 14(Wed.) 16:05-16:20 |
|---|
| National Institute of Advanced Industrial Science and Technology (AIST) |
|
Nobutaka NAKASHIMA Group Leader, Bioproduction Research Institute |
Metabolic engineering of bacteria and production of value-added compounds |
| Presentation Stage A | October 14(Wed.) 16:20-16:35 |
|---|
| bitBiome, Inc. |
|
Masahito HOSOKAWA CSO |
Single-cell genomics for making uncultured microbes resource |
| Presentation Stage A | October 16(Fri.) 13:40-14:10 |
|---|
| Japan Agency for Marine Earth Science and Technology (JAMSTEC) |
| healthTECH / ME-BYO Stage | October 14(Wed.) 16:00-17:00 |
|---|
| Kantou Bureau of Economy, Trade and Industry/SUSMED/PREVENT/Moff |
|
Kantou Bureau of Economy, Trade and Industry/SUSMED/PREVENT/Moff |
| Presentation Stage B | October 16(Fri.) 11:40-12:10 |
|---|
| St.Marianna University School of Medicine |
|
Yasuyuki Kobayashi |
| healthTECH / ME-BYO Stage | October 14(Wed.) 14:40-14:50 |
|---|
| MOLCURE Inc., |
|
Ryu Ogawa CEO |
Peptides and antibodies design via AI and directed evolutionMOLCURE provides drug discovery support service "Peptide and antibody molecule design using artificial intelligence, advanced molecular engineering, and next-generation sequencing" for pharmaceutical companies. Our service ... |
| healthTECH / ME-BYO Stage | October 14(Wed.) 15:25-15:35 |
|---|
| Mitsui Knowledge Industry Co., Ltd. |
|
Ryota Teshima Bioscience Div., Solution Knowledge Center |
| Presentation Stage A | October 15(Thu.) 10:20-10:50 |
|---|
| GlycoTechnica Ltd. |
|
Sayuki Iijima |
Elucidation of the Pathogenesis of Viral Infections and their Possible Treatment Strategies Using a Lectin Microarray SystemGlycosylation is a post-translational modification of proteins and plays important roles in the regulation of protein functions, cell-to-cell communications, and viral infections. Glycan recognition by ... |
| Presentation Stage A | October 15(Thu.) 14:50-15:00 |
|---|
|
Gmep Incorporated
Fukuoka Prefectural Bio Industry Center Promotion Conference |
|
Ken-ichi Kusumoto |
Introduction of GMEP CD medium for mammalian cell cultureSince 1999, we have consistently pursued on serum-free culture for mammalian cells. And our GMEP succeeded in the development of chemically defined medium for HEK293 ... |
| Presentation Stage A | October 15(Thu.) 15:30-16:00 |
|---|
| Research Institute for Animal Science in Biochemistry and Toxicology / MARUBENI CHEMIX CORPORATION |
| Presentation Stage B | October 15(Thu.) 11:40-12:10 |
|---|
| Doshisha University |
|
MIYASAKA Tomohiro Faculty of Life and Medical Sciences |
Immunohistochemical detection method for unaggregated phosphorylated tauTauopathies are neurodegenerative diseases, including Alzheimer's disease (AD), characterized by the deposition of abnormal tau protein in the affected neurons. Although, the mechanisms of the ... |
| Presentation Stage B | October 15(Thu.) 15:40-16:10 |
|---|
| Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University |
|
Seiji Okada Professor |
Establishment of highly immunocompromised mice and transplantation needle optimized for patient-derived tumor xenograft (PDX)Patient-derived xenograft (PDX) models are created by engraftment of patient tumor tissues into immunocompromised mice. Since a PDX model retains the characteristics of the primary ... |
| healthTECH / ME-BYO Stage | October 15(Thu.) 15:30-15:40 |
|---|
| MOLCURE Inc., |
|
Shoji Ihara CCO |
Peptides and antibodies design via AI and directed evolutionMOLCURE provides drug discovery support service "Peptide and antibody molecule design using artificial intelligence, advanced molecular engineering, and next-generation sequencing" for pharmaceutical companies. Our service ... |
| healthTECH / ME-BYO Stage | October 15(Thu.) 15:50-16:00 |
|---|
| Mitsui Knowledge Industry Co., Ltd. |
|
Takato Sato Bioscience Div., Solution Knowledge Center |
| Presentation Stage A | October 16(Fri.) 15:40-15:55 |
|---|
| MaxWell Biosystems (Presentation in English) |
|
Dr. Marie Obien |
High-Content Electrophysiology for Characterizing Human iPSC-derived Neurons and Effects of Compounds |
| healthTECH / ME-BYO Stage | October 16(Fri.) 11:00-11:10 |
|---|
| MOLCURE Inc., |
|
Yutaro Kyono CTO |
Peptides and antibodies design via AI and directed evolutionMOLCURE provides drug discovery support service "Peptide and antibody molecule design using artificial intelligence, advanced molecular engineering, and next-generation sequencing" for pharmaceutical companies. Our service ... |
| healthTECH / ME-BYO Stage | October 16(Fri.) 15:50-16:00 |
|---|
| Mitsui Knowledge Industry Co., Ltd. |
|
Takato Sato Bioscience Div., Solution Knowledge Center |
| Presentation Stage C | October 15(Thu.) 13:40-14:10 |
|---|
| Waseda University |
|
Mototoki Tominaga Associate Professor |
Success in promoting plant growth for biodieselCytoplasmic streaming is seen in any plant as an active cytoplasmic movement with organelles, such as the endoplasmic reticulum. It is known that cytoplasmic streaming ... |
| Presentation Stage A | October 15(Thu.) 15:10-15:20 |
|---|
| Fukuoka Prefectural Bio Industry Center Promotion Conference |
CUBIC-HV: the world-best whole-organ staining and imaging techniqueBecause biological tissues have a three-dimensional (3D) structure, it is necessary to observe and analyze their structure in three dimensions. However, the opaque nature of ... |
| Presentation Stage B | October 15(Thu.) 13:40-14:10 |
|---|
| Nagasaki University |
|
Tomoshi Tsuchiya Department of Surgical Oncology Associate Professor |
An ex-vivo cancer therapy evaluation model that reproduces the in vivo microenvironmentUntil now, cancer cells grown on 2D culture dishes have been used for the screening of anticancer drugs. But many cells grown on 2D culture ... |
| Presentation Stage A | October 14(Wed.) 13:40-14:10 |
|---|
| Hamamatsu University School of Medicine |
|
Yuko Amano Promotion Center for Medical Collaboration and Intellectual Property |
Introduction of Research Seeds and Medical Needs in HUSMIntroduction of Research Seeds and Medical Needs in HUSM |
| RM Stage | October 14(Wed.) 13:40-14:10 |
|---|
Simultaneous Interpretation
| IQVIA Japan Group (Presentation in English) |
|
Alan Thomas Thought Leadership |
Seizing Opportunities in the Second Largest Innovation Driven Pharmaceutical MarketJapan is - and will remain - the second largest market for branded pharmaceuticals and innovation. Continued investment in development and commercialization of pharmaceuticals in ... |
| healthTECH / ME-BYO Stage | October 14(Wed.) 15:15-15:25 |
|---|
| zenius Ltd. |
|
Yui Muguruma CEO |
A Red Dot Design Award winning design consultancy talks about Importance of drug delivery device designzeniud Ltd. has been supporting many of the worlds' leading pharma as well as manufacturers of drug delivery devices globally, accelerating their device development processes ... |
| Presentation Stage A | October 15(Thu.) 14:20-14:30 |
|---|
| Fukuoka Prefectural Bio Industry Center Promotion Conference |
|
Junetsu Igarashi Fukuoka Bio Valley Project Director |
Introduction and achievement of Fukuoka Bio ValleyProjectFukuoka Prefecture is promoting the Fukuoka BioValley Project, which creates a bio industry and forms a large concentration base for related companies and research institutes ... |
| Presentation Stage B | October 15(Thu.) 14:20-14:50 |
|---|
| TOKYO INSTITUTE OF TECHNOLOGY |
|
TAKANORI HIOKI,CHIAKI SEINO,MACHIKO NAKATOGAWA OFFICE of Research and Innovation,URA,specially appointed professor |
| Presentation Stage C | October 15(Thu.) 11:40-12:10 |
|---|
| Nagoya University |
|
Shigeo Arai Professor |
Observation of the biological samples using high-performance electron microscopeNagoya University supports a molecular biologic study by a high voltage electron microscopy (HVEM) and excellent electron microscopes. These microscopes are very used by many ... |
| healthTECH / ME-BYO Stage | October 15(Thu.) 11:00-11:10 |
|---|
| zenius Ltd. |
|
Yui Muguruma CEO |
A Red Dot Design Award winning design consultancy talks about Importance of drug delivery device designzeniud Ltd. has been supporting many of the worlds' leading pharma as well as manufacturers of drug delivery devices globally, accelerating their device development processes ... |
| healthTECH / ME-BYO Stage | October 16(Fri.) 11:10-11:20 |
|---|
| zenius Ltd. |
|
Yui Muguruma CEO |
A Red Dot Design Award winning design consultancy talks about Importance of drug delivery device designzeniud Ltd. has been supporting many of the worlds' leading pharma as well as manufacturers of drug delivery devices globally, accelerating their device development processes ... |
